Ariad Pharmaceuticals (ARIA) 14.66 -0.305

Ariad Pharmaceuticals, Inc.
(ARIA) 14.66 -0.305

Last Trade:	14.655	Day Range:	14.42 - 14.97
Trade Time:	08:02PM	52wk Range:	5.52 - 15.98
Prev. Close:	14.96	Market Cap:	2.31B
Open:	14.88	Div Yield:	0
Volume:	3335874	PE:
EPS:	-0.85

The Latest On ARIA

Weekly Traders Homework: The First Sign Of Weakness In 2012 (w/ Economic Calendar & Stock Radar) 2/12/12 10:52pm

Notable Put Options Activity in ARIAD Pharmaceuticals 2/2/12 1:33pm

Bullish setups that you should watch next week 1/15/12 2:12pm

Rodman & Renshaw Maintains Outperform, $18 PT on Ariad Pharmaceuticals 1/11/12 9:05am

Benzinga's Volume Gainers 1/4/12 2:26pm

ARIAD to Trade on the NASDAQ Global Select Market 1/3/12 7:35am

Notable Put Options Activity on ARIAD Pharmaceuticals 12/27/11 11:59am

Best Biotech Stocks of 2011 12/27/11 10:39am

Rodman & Renshaw Raises PT on ARIAD Pharma to $18 12/27/11 7:52am

Notable Put Options Activity in ARIAD Pharmaceuticals 12/19/11 11:09am

Weekly Homework: Are Bonds Trying To Tell Us Something? (w/ Economic Calendar & Stock Radar) 12/18/11 11:28pm

ARIAD Announces Underwriters' Exercise of Over-Allotment Option 12/16/11 9:20am

Weekly Traders Homework: The First Sign Of Weakness In 2012 (w/ Economic Calendar & Stock Radar) 2/12/12

Notable Put Options Activity in ARIAD Pharmaceuticals 2/2/12

Bullish setups that you should watch next week 1/15/12

Rodman & Renshaw Maintains Outperform, $18 PT on Ariad Pharmaceuticals 1/11/12

Benzinga's Volume Gainers 1/4/12

ARIAD to Trade on the NASDAQ Global Select Market 1/3/12

Notable Put Options Activity on ARIAD Pharmaceuticals 12/27/11

Best Biotech Stocks of 2011 12/27/11

Rodman & Renshaw Raises PT on ARIAD Pharma to $18 12/27/11

Notable Put Options Activity in ARIAD Pharmaceuticals 12/19/11

Weekly Homework: Are Bonds Trying To Tell Us Something? (w/ Economic Calendar & Stock Radar) 12/18/11

ARIAD Announces Underwriters' Exercise of Over-Allotment Option 12/16/11

Weekly Traders Homework: The First Sign Of Weakness In 2012 (w/ Economic Calendar & Stock Radar) 2/12/12

Bullish setups that you should watch next week 1/15/12

Best Biotech Stocks of 2011 12/27/11

Weekly Homework: Are Bonds Trying To Tell Us Something? (w/ Economic Calendar & Stock Radar) 12/18/11

Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar) 12/11/11

Six Stocks Under $10 Lottery Specials 10/7/11

Mad Money Lightning Round: Cramer Likes Starbucks, BJ's Restaurants 8/16/11

Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows 7/20/11

Stocks to Watch for Monday 7/18/2011: Fresh 52 Week Highs and Lows 7/17/11

Stocks to Watch for Tuesday 07/12/11: Fresh 52 Week Highs and Lows 7/11/11

Stocks to Watch for Monday 07/11/11: Fresh 52 Week Highs and Lows 7/10/11

Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows 6/29/11

Rodman & Renshaw Maintains Outperform, $18 PT on Ariad Pharmaceuticals 1/11/12

Benzinga's Volume Gainers 1/4/12

Rodman & Renshaw Raises PT on ARIAD Pharma to $18 12/27/11

Bank of America Maintains Neutral, $14 PT on Ariad Pharmaceuticals 12/12/11

Jefferies Maintains Buy Rating on Ariad Pharma 12/12/11

J.P. Morgan Maintains Overweight Rating on Ariad Pharmaceuticals 12/12/11

Jefferies Maintains Buy Rating and $16 PT on ARIAD Pharmaceuticals 12/2/11

Rodman & Renshaw Maintain Market Outperform Rating and $15 PT on ARIAD Pharmaceuticals 11/4/11

Rodman & Renshaw Maintain Market Outperform Rating and $15 PT on ARIAD Pharmaceuticals 11/1/11

Rodman & Renshaw Initiates ARIAD Pharmaceuticals at Market Outperform, $15 PT 10/14/11

BofA/ML Reiterates Neutral Rating on Ariad Pharmaceuticals 9/26/11

UPDATE: Oppenheimer Raises Price Target On Ariad Pharmaceuticals To $17 9/14/11

Trade ARIA
NOW!

Partner Headlines

J.P. Morgan Biotech Confab Live Chat 1/10/12

8 Stocks Hitting New Highs Today 1/6/12

6 Stocks Rising on Huge Volume 12/15/11

Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting 12/12/11

10 Biotech Stocks Loved and Hated By Wall Street's Top Investment Pros 11/15/11

Biotech Stock Mailbag: Ariad, Amarin, Arena 11/11/11

Ariad Pharma: Early Efficacy, Safety of Leukemia Drug 'Striking' 11/7/11

5 Stocks Under $10 With Big Upside Potential 10/6/11

Zacks #5 Rank Additions for Tuesday - Tale of the Tape 10/4/11

10 Small Caps Flashing Buy Signs 9/1/11

Press Releases

Mintz Levin's Life Sciences Practice Represents Clients in More Than $3 Billion in Life Sciences Deals in 2011 2/6/12 Business Wire Story

ARIAD to Present at Upcoming Investor Conferences 2/2/12 Business Wire Story

ARIAD to Present at the 30th Annual J.P. Morgan Healthcare Conference 1/4/12 Business Wire Story

ARIAD to Trade on the NASDAQ Global Select Market 1/3/12 Business Wire Story

ARIAD Announces Completion of Public Offering 12/20/11 Business Wire Story

ARIAD Announces Underwriters' Exercise of Over-Allotment Option 12/16/11 Business Wire Story

ARIAD Announces Pricing of Public Offering of Common Stock 12/15/11 Business Wire Story

ARIAD Announces Proposed Public Offering of Common Stock 12/14/11 Business Wire Story

ARIAD Announces Preliminary Data from Pivotal Pace Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor 12/11/11 Business Wire Story

ARIAD to Present at the Oppenheimer 22nd Annual Healthcare Conference 12/6/11 Business Wire Story

ARIAD Announces Investor Meeting and Webcast at American Society of Hematology Meeting 12/5/11 Business Wire Story

ARIAD to Present at the 2011 Deutsche Bank BioFEST 11/28/11 Business Wire Story

Get the latest ARIA stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Ariad Pharmaceuticals, Inc. stock price.

Ariad Pharmaceuticals, Inc. by YCharts